Search

Your search keyword '"Chaigneau, L."' showing total 290 results

Search Constraints

Start Over You searched for: Author "Chaigneau, L." Remove constraint Author: "Chaigneau, L."
290 results on '"Chaigneau, L."'

Search Results

1. Improved nationwide survival of sarcoma patients with a network of reference centers

2. A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

3. Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years

4. VP3-2024: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

5. 55O IMADGIST: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

6. A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial

8. Surgery in reference centers improves survival of sarcoma patients: a nationwide study

9. Cancer(s) du sein

13. 1512P Pain in patients with desmoid fibromatosis (DF)

14. Conservative surgery vs. duodeneopancreatectomy in primary duodenal gastrointestinal stromal tumors (GIST): A retrospective review of 114 patients from the French Sarcoma Group (FSG)

16. 1761P Clinical description and development of a prognosis score for neurofibromatosis type 1 (NF1) associated GISTs in the RECKGIST cohort: A retrospective study from the French NETSARC+ network

17. 1760P Impact of adjuvant imatinib on recurrence for neurofibromatosis type 1 (NF1) associated GISTs: An analysis of the RECKGIST cohort from the French NETSARC+ network

18. 1718O EREMISS trial: A double-blind placebo (PBO)-controlled randomised trial assessing efficacy/safety of regorafenib (REGO) as maintenance therapy after 1st line doxorubicin-based chemotherapy in advanced soft-tissue sarcoma (ASTS) patients (pts)

23. 822TiP BFR ESS: A randomized phase II trial from the GSF/GETO French group evaluating the impact of interruption versus maintenance of aromatase inhibitors in patients with advanced or metastatic low grade endometrial stromal sarcoma after at least 3 years of therapy

27. Recommandations pour la pratique clinique : Standards, Options : Recommandations 2008 pour la prise en charge des patientes atteintes de tumeurs épithéliales malignes de l’ovaire. Traitement médical de première ligne (rapport abrégé)

32. Osteosarcomas of the mandible: multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO, Rare Cancer Network, GETTEC/REFCOR and SFCE†

40. A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)

41. Correction to: Surgery in reference centers improves survival of sarcoma patients: a nationwide study

42. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

45. Prolonged overall survival for patients with bone-only metastases at presentation of metastatic breast cancer

46. Impact of BRCA status on outcomes and survival in high-risk early breast cancers

48. Real-life study of BRCA genetic screening in metastatic breast cancer

49. SToRM: A clinical cohort to identify genetic variability related to metastatic phenotypes

50. LBA15_PR - A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)

Catalog

Books, media, physical & digital resources